ID   PPMI.I.1099.1
AC   CVCL_D5TU
SY   PPMI51867; PPMI_51867; CDIi024-A; FCDI_11305
DR   BioSamples; SAMEA115473782
DR   hPSCreg; CDIi024-A
DR   Wikidata; Q127383529
RX   PubMed=34434090;
WW   Info; PPMI; -; https://www.michaeljfox.org/sites/default/files/media/document/2018%20-%20PDTC%20-%20NKP%20Poster%20on%20iPSCs.pdf
WW   Info; PPMI; -; https://www.ppmi-info.org/access-data-specimens/download-data
CC   Part of: Parkinson's Progression Markers Initiative (PPMI) cell line panel.
CC   Sequence variation: Mutation; HGNC; HGNC:18618; LRRK2; Simple; p.Gly2019Ser (c.6055G>A); ClinVar=VCV000001940; Zygosity=Heterozygous (from autologous cell line PPMI.I.1099.3).
CC   Donor information: At sampling donor was not affected with Parkinson disease but at risk for disease. Was suffering from hyposmia.
CC   Miscellaneous: PPMI study cohort prodromal, PPMI study subgroup LRRK2 + hyposmia.
CC   Caution: The PPMI51867 and PPMI_51867 identifiers correspond to an internal donor ID at PPMI. As multiple iPSC clones have been established from the cells of this donor, these identifiers should not be cited in a publication. Note that FujiFilm Cellular Dynamics, Inc (FCDI) and hPSCreg have assigned only a single identifier for all of the PBMC derived clones.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
DI   NCIt; C198605; Parkinson disease 8, autosomal dominant
DI   ORDO; Orphanet_411602; Hereditary late-onset Parkinson disease
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_D5TV ! PPMI.I.1099.2
OI   CVCL_D5TW ! PPMI.I.1099.3
SX   Female
AG   65Y
CA   Induced pluripotent stem cell
DT   Created: 02-05-24; Last updated: 10-04-25; Version: 4
//
RX   PubMed=34434090; DOI=10.3389/fnmol.2021.734273; PMCID=PMC8381147;
RA   Nguyen, David
RA   Bharat, Vinita
RA   Conradson, Devon M.
RA   Nandakishore, Pawan
RA   Wang, Xin-Nan
RT   "Miro1 impairment in a Parkinson's at-risk cohort.";
RL   Front. Mol. Neurosci. 14:734273.1-734273.8(2021).
//